希少腎臓病の世界市場レポート 2025年

希少腎臓病市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR10.1％で44億9,000万米ドルに成長します。予測期間の成長は、遺伝子治療の出現、希少疾患調査への投資の増加、利害関係者間の協力関係の拡大、希少疾患に対する世界の取り組みに起因しています。予測期間の世界の動向には、患者中心のアプローチ、実世界のエビデンスとデータ分析、規制の進展、遠隔医療と遠隔モニタリング、世界ヘルスへの取り組みなどが含まれます。

希少腎臓病市場の予想成長は、腎臓病に対する政府の取り組みと資金援助によって推進されると予想されます。政府の支援は、財政支援という形で、公共サービスや経済の改善に貢献するプロジェクトやアイデアを持つ事業体に向けられています。具体的には、米国下院歳出委員会は2022年7月、腎臓の健康を促進するためのさまざまな投資プログラムを開始し、疾病対策予防センターの慢性腎臓病プログラムに850万米ドルを割り当てた。この資金は、腎臓病の認知度向上、診断、治療への取り組みを加速させることを目的としています。さらに、国立生体腎ドナー支援センターには100万米ドルの投資が予定されており、合計800万米ドルが技術革新と研究に継続的に投資されることになります。このように、政府のイニシアティブと資金援助は希少腎臓病市場の成長促進要因となっています。

慢性腎臓病（CKD）の有病率の大幅な増加は、希少腎臓病市場の成長に大きく寄与しています。CKDは腎臓の障害と血液のろ過機能障害を特徴とし、発症リスクを高める。米国疾病予防管理センター（CDC）の2023年の報告書によると、米国成人の約14％、約3,550万人が慢性腎臓病であると推定されています。このようなCKD有病率の増加は、希少腎臓病に対処する治療薬に対する需要の増加につながり、市場の拡大を促進すると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界希少腎臓病 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の希少腎臓病市場：成長率分析
• 世界の希少腎臓病市場の実績：規模と成長, 2019-2024
• 世界の希少腎臓病市場の予測：規模と成長, 2024-2029, 2034F
• 世界希少腎臓病総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の希少腎臓病市場対象適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• IgA腎症
• ループス腎炎
• 局所性分節性糸球体硬化症
• 膜性腎症
• C3糸球体症
• その他の対象適応症
• 世界の希少腎臓病市場分子の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小分子
• 生物学的製剤
• 世界の希少腎臓病市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 静脈内
• 皮下
• その他の投与経路
• 世界の希少腎臓病市場、IgA腎症のサブセグメンテーション、対象適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫抑制療法
• 支持療法と症状管理
• 世界の希少腎臓病市場、ループス腎炎のサブセグメンテーション、対象適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• コルチコステロイド
• 抗マラリア薬
• 生物学的製剤
• 世界の希少腎臓病市場、標的適応症による巣状糸球体硬化症（FSGS）のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• コルチコステロイド
• アンジオテンシン受容体拮抗薬（ARB）
• その他の免疫抑制剤
• 世界の希少腎臓病市場膜性腎症のサブセグメンテーション、対象適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• コルチコステロイド
• 免疫抑制療法
• モノクローナル抗体
• 世界の希少腎臓病市場、C3糸球体症のサブセグメンテーション、対象適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 補体阻害薬
• 支持療法
• 免疫抑制療法
• 世界の希少腎臓病市場、その他の対象適応症のサブセグメンテーション、対象適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アルポート症候群
• 薄基底膜腎症
• その他の稀な腎臓疾患

第7章 地域別・国別分析

• 世界の希少腎臓病市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の希少腎臓病市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 希少腎臓病市場：競合情勢
• 希少腎臓病市場：企業プロファイル
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Otsuka Pharmaceutical Co Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Alexion Pharmaceuticals Inc.
• Horizon Therapeutics plc.
• Recordati S.p.A.
• Amicus Therapeutics Inc.
• Akebia Therapeutics Inc.
• Travere Therapeutics
• FibroGen Inc.
• Aurinia Pharmaceuticals Inc.
• Calliditas Therapeutics AB
• Apellis Pharmaceuticals Inc.
• Protalix Biotherapeutics Inc.
• ChemoCentryx Inc.
• Omeros Corporation
• Celtaxsys Inc.
• Corbus Pharmaceuticals Holdings Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 希少腎臓病市場2029：新たな機会を提供する国
• 希少腎臓病市場2029：新たな機会を提供するセグメント
• 希少腎臓病市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Rare kidney disease refers to a condition in which the kidneys do not function correctly, leading to the accumulation of waste in the body and causing health problems. This group of renal diseases has a low frequency in the general population and often has a genetic or hereditary origin.

The primary target indications for rare kidney diseases include IgA nephropathy, lupus nephritis, focal segmental glomerular sclerosis, membranous nephropathy, C3 glomerulopathy, and others. IgA nephropathy is a kidney disease characterized by the accumulation of antibodies (known as IgA) in kidney tissue, leading to inflammation. Treatment involves the use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) to lower blood pressure, reduce protein loss, slow the progression of kidney damage, manage symptoms, and prevent complications. The various types of molecules involved in treatment include small molecules and biologics, which are administered through various routes such as oral, intravenous, subcutaneous, and others.

The rare kidney diseases market research report is one of a series of new reports from The Business Research Company that provides Rare Kidney Diseases market statistics, including Rare Kidney Diseases industry global market size, regional shares, competitors with a Rare Kidney Diseases market share, detailed Rare Kidney Diseases market segments, market trends, and opportunities, and any further data you may need to thrive in the Rare Kidney Diseases industry. This Rare Kidney Diseases market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The rare kidney diseases market size has grown rapidly in recent years. It will grow from $2.76 billion in 2024 to $3.06 billion in 2025 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to increased disease recognition, orphan drug designations, patient advocacy and awareness, and global collaborations in research

The rare kidney diseases market size is expected to see rapid growth in the next few years. It will grow to $4.49 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to the emergence of gene therapies, increasing investment in rare disease research, growing collaboration between stakeholders, and global initiatives for rare diseases. Major trends in the forecast period include a patient-centric approach, real-world evidence and data analytics, regulatory developments, telemedicine and remote monitoring, and global health initiatives.

The anticipated growth of the rare kidney disease market is expected to be propelled by government initiatives and funding for kidney disorders. Government support, in the form of financial assistance, is directed towards entities with projects and ideas that contribute to improving public services and the economy. Specifically, in July 2022, The United States House Committee on Appropriations initiated various investment programs to promote kidney health, allocating $8.5 million for the Centers for Disease Control and Prevention's chronic kidney disease program. This funding aims to accelerate efforts in raising awareness, diagnosis, and treatment of kidney disease. Additionally, a $1 million investment was earmarked for the national living donor assistance center, totaling $8 million in ongoing investment in innovation and research. Thus, government initiatives and funding are key drivers of growth in the rare kidney disease market.

The significant increase in the prevalence of chronic kidney disease (CKD) is a substantial contributor to the growth of the rare kidney disease market. CKD, characterized by kidney damage and impaired blood filtering, elevates the risk of developing rare kidney diseases. According to the 2023 report from the Centers for Disease Control and Prevention (CDC), approximately 14% of US adults, around 35.5 million people, are estimated to have chronic kidney disease. This rise in CKD prevalence is expected to lead to an increased demand for therapeutics addressing rare kidney diseases, thereby driving the market's expansion.

Innovation in product development stands out as a prominent trend gaining traction in the rare kidney disease market. Major players in the market are strategically focusing on creating innovative products to fortify their market positions. For example, in September 2022, STADA Arzneimittel AG introduced Kinpeygo (budesonide), the first EU-authorized medicine for treating a rare kidney disease, specifically immunoglobulin A nephropathy (IgAN). This modified-release budesonide capsule represents a significant advancement in addressing the high unmet need in primary IgAN, a rare autoimmune kidney disease with a considerable impact on patients.

Companies operating in the rare kidney disease market are specifically emphasizing the development of non-immunosuppressive therapy. This unique treatment approach caters to patients with progressive kidney diseases, offering an alternative to traditional therapies for rare kidney diseases. For instance, in February 2023, Travere Therapeutics launched sparsentan, commercially known as Filspari, the first non-immunosuppressive therapy approved for primary immunoglobulin A nephropathy (IgAN). Filspari operates through a distinct mode of action by blocking angiotensin and endothelin receptors, setting it apart from conventional treatments such as ACE inhibitors and ARBs.

In February 2023, AstraZeneca Pharmaceuticals LP acquired CinCor Pharma Inc. for $1.8 billion. This acquisition positions AstraZeneca Pharmaceuticals LP to enhance its portfolio in chronic renal illness and uncontrolled hypertension, as CinCor Pharma Inc. brings valuable medications for rare kidney diseases to the company's offerings.

Major companies operating in the rare kidney diseases market include Merck & Co. Inc., Novartis AG, Sanofi S.A, AstraZeneca plc, Otsuka Pharmaceutical Co Ltd., Alexion Pharmaceuticals Inc., Horizon Therapeutics plc., Recordati S.p.A., Amicus Therapeutics Inc., Akebia Therapeutics Inc., Travere Therapeutics, FibroGen Inc., Aurinia Pharmaceuticals Inc., Calliditas Therapeutics AB, Apellis Pharmaceuticals Inc., Protalix Biotherapeutics Inc., ChemoCentryx Inc., Omeros Corporation, Celtaxsys Inc., Corbus Pharmaceuticals Holdings Inc., Chinook Therapeutics Inc., OxThera AB, Advicenne Pharma SA, Reata Pharmaceuticals Inc., Savara Inc.

North America was the leading region in the rare kidney disease market in 2024. The regions covered in the rare kidney diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the rare kidney diseases market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The rare kidney disease market includes revenues earned by entities by providing services clinical evaluation, genetic counseling, genetic screening, specific testing, molecular diagnosis, hemodialysis, and peritoneal dialysis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Rare Kidney Diseases Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on rare kidney diseases market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for rare kidney diseases ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The rare kidney diseases market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Target Indication: IgA Nephropathy; Lupus Nephritis; Focal Segmental Glomerular Sclerosis; Membranous Nephropathy; C3 Glomerulopathy; Other Target Indications
• 2) By Type Of Molecule: Small Molecules; Biologics
• 3) By Route Of administration: Oral; Intravenous; Subcutaneous; Other Routes Of Administration
• Subsegments:
• 1) By IgA Nephropathy: Immunosuppressive Therapy; Supportive Care And Symptomatic Management
• 2) By Lupus Nephritis: Corticosteroids; Antimalarial Agents; Biologics
• 3) By Focal Segmental Glomerular Sclerosis (FSGS): Corticosteroids; Angiotensin Receptor Blockers (ARBs); Other Immunosuppressive Agents
• 4) By Membranous Nephropathy: Corticosteroids; Immunosuppressive Therapy; Monoclonal Antibodies
• 5) By C3 Glomerulopathy: Complement Inhibitors; Supportive Care; Immunosuppressive Therapies
• 6) By Other Target Indications: Alport Syndrome; Thin Basement Membrane Nephropathy; Other Rare Kidney Disorders
• Companies Mentioned: Merck & Co. Inc.; Novartis AG; Sanofi S.A; AstraZeneca plc; Otsuka Pharmaceutical Co Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Rare Kidney Diseases Market Characteristics

3. Rare Kidney Diseases Market Trends And Strategies

4. Rare Kidney Diseases Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Rare Kidney Diseases Growth Analysis And Strategic Analysis Framework

• 5.1. Global Rare Kidney Diseases PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Rare Kidney Diseases Market Growth Rate Analysis
• 5.4. Global Rare Kidney Diseases Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Rare Kidney Diseases Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Rare Kidney Diseases Total Addressable Market (TAM)

6. Rare Kidney Diseases Market Segmentation

• 6.1. Global Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• IgA Nephropathy
• Lupus Nephritis
• Focal Segmental Glomerular Sclerosis
• Membranous Nephropathy
• C3 Glomerulopathy
• Other Target Indications
• 6.2. Global Rare Kidney Diseases Market, Segmentation By Type Of Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Small Molecules
• Biologics
• 6.3. Global Rare Kidney Diseases Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• Subcutaneous
• Other Routes Of Administration
• 6.4. Global Rare Kidney Diseases Market, Sub-Segmentation Of IgA Nephropathy, By Target Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunosuppressive Therapy
• Supportive Care And Symptomatic Management
• 6.5. Global Rare Kidney Diseases Market, Sub-Segmentation Of Lupus Nephritis, By Target Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroids
• Antimalarial Agents
• Biologics
• 6.6. Global Rare Kidney Diseases Market, Sub-Segmentation Of Focal Segmental Glomerular Sclerosis (FSGS), By Target Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroids
• Angiotensin Receptor Blockers (ARBs)
• Other Immunosuppressive Agents
• 6.7. Global Rare Kidney Diseases Market, Sub-Segmentation Of Membranous Nephropathy, By Target Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroids
• Immunosuppressive Therapy
• Monoclonal Antibodies
• 6.8. Global Rare Kidney Diseases Market, Sub-Segmentation Of C3 Glomerulopathy, By Target Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Complement Inhibitors
• Supportive Care
• Immunosuppressive Therapies
• 6.9. Global Rare Kidney Diseases Market, Sub-Segmentation Of Other Target Indications, By Target Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alport Syndrome
• Thin Basement Membrane Nephropathy
• Other Rare Kidney Disorders

7. Rare Kidney Diseases Market Regional And Country Analysis

• 7.1. Global Rare Kidney Diseases Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Rare Kidney Diseases Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Rare Kidney Diseases Market

• 8.1. Asia-Pacific Rare Kidney Diseases Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Rare Kidney Diseases Market, Segmentation By Type Of Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Rare Kidney Diseases Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Rare Kidney Diseases Market

• 9.1. China Rare Kidney Diseases Market Overview
• 9.2. China Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Rare Kidney Diseases Market, Segmentation By Type Of Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Rare Kidney Diseases Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Rare Kidney Diseases Market

• 10.1. India Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Rare Kidney Diseases Market, Segmentation By Type Of Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Rare Kidney Diseases Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Rare Kidney Diseases Market

• 11.1. Japan Rare Kidney Diseases Market Overview
• 11.2. Japan Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Rare Kidney Diseases Market, Segmentation By Type Of Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Rare Kidney Diseases Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Rare Kidney Diseases Market

• 12.1. Australia Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Rare Kidney Diseases Market, Segmentation By Type Of Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Rare Kidney Diseases Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Rare Kidney Diseases Market

• 13.1. Indonesia Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Rare Kidney Diseases Market, Segmentation By Type Of Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Rare Kidney Diseases Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Rare Kidney Diseases Market

• 14.1. South Korea Rare Kidney Diseases Market Overview
• 14.2. South Korea Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Rare Kidney Diseases Market, Segmentation By Type Of Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Rare Kidney Diseases Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Rare Kidney Diseases Market

• 15.1. Western Europe Rare Kidney Diseases Market Overview
• 15.2. Western Europe Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Rare Kidney Diseases Market, Segmentation By Type Of Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Rare Kidney Diseases Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Rare Kidney Diseases Market

• 16.1. UK Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Rare Kidney Diseases Market, Segmentation By Type Of Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Rare Kidney Diseases Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Rare Kidney Diseases Market

• 17.1. Germany Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Rare Kidney Diseases Market, Segmentation By Type Of Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Rare Kidney Diseases Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Rare Kidney Diseases Market

• 18.1. France Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Rare Kidney Diseases Market, Segmentation By Type Of Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Rare Kidney Diseases Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Rare Kidney Diseases Market

• 19.1. Italy Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Rare Kidney Diseases Market, Segmentation By Type Of Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Rare Kidney Diseases Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Rare Kidney Diseases Market

• 20.1. Spain Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Rare Kidney Diseases Market, Segmentation By Type Of Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Rare Kidney Diseases Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Rare Kidney Diseases Market

• 21.1. Eastern Europe Rare Kidney Diseases Market Overview
• 21.2. Eastern Europe Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Rare Kidney Diseases Market, Segmentation By Type Of Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Rare Kidney Diseases Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Rare Kidney Diseases Market

• 22.1. Russia Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Rare Kidney Diseases Market, Segmentation By Type Of Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Rare Kidney Diseases Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Rare Kidney Diseases Market

• 23.1. North America Rare Kidney Diseases Market Overview
• 23.2. North America Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Rare Kidney Diseases Market, Segmentation By Type Of Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Rare Kidney Diseases Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Rare Kidney Diseases Market

• 24.1. USA Rare Kidney Diseases Market Overview
• 24.2. USA Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Rare Kidney Diseases Market, Segmentation By Type Of Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Rare Kidney Diseases Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Rare Kidney Diseases Market

• 25.1. Canada Rare Kidney Diseases Market Overview
• 25.2. Canada Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Rare Kidney Diseases Market, Segmentation By Type Of Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Rare Kidney Diseases Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Rare Kidney Diseases Market

• 26.1. South America Rare Kidney Diseases Market Overview
• 26.2. South America Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Rare Kidney Diseases Market, Segmentation By Type Of Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Rare Kidney Diseases Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Rare Kidney Diseases Market

• 27.1. Brazil Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Rare Kidney Diseases Market, Segmentation By Type Of Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Rare Kidney Diseases Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Rare Kidney Diseases Market

• 28.1. Middle East Rare Kidney Diseases Market Overview
• 28.2. Middle East Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Rare Kidney Diseases Market, Segmentation By Type Of Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Rare Kidney Diseases Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Rare Kidney Diseases Market

• 29.1. Africa Rare Kidney Diseases Market Overview
• 29.2. Africa Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Rare Kidney Diseases Market, Segmentation By Type Of Molecule, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Rare Kidney Diseases Market, Segmentation By Route Of administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Rare Kidney Diseases Market Competitive Landscape And Company Profiles

• 30.1. Rare Kidney Diseases Market Competitive Landscape
• 30.2. Rare Kidney Diseases Market Company Profiles
  • 30.2.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi S.A Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Otsuka Pharmaceutical Co Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Rare Kidney Diseases Market Other Major And Innovative Companies

• 31.1. Alexion Pharmaceuticals Inc.
• 31.2. Horizon Therapeutics plc.
• 31.3. Recordati S.p.A.
• 31.4. Amicus Therapeutics Inc.
• 31.5. Akebia Therapeutics Inc.
• 31.6. Travere Therapeutics
• 31.7. FibroGen Inc.
• 31.8. Aurinia Pharmaceuticals Inc.
• 31.9. Calliditas Therapeutics AB
• 31.10. Apellis Pharmaceuticals Inc.
• 31.11. Protalix Biotherapeutics Inc.
• 31.12. ChemoCentryx Inc.
• 31.13. Omeros Corporation
• 31.14. Celtaxsys Inc.
• 31.15. Corbus Pharmaceuticals Holdings Inc.

32. Global Rare Kidney Diseases Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Rare Kidney Diseases Market

34. Recent Developments In The Rare Kidney Diseases Market

35. Rare Kidney Diseases Market High Potential Countries, Segments and Strategies

• 35.1 Rare Kidney Diseases Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Rare Kidney Diseases Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Rare Kidney Diseases Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer